GSK Bulks Up Discovery Work in $99M Cellzome Acquisition
By Catherine Shaffer
Wednesday, May 16, 2012
Cellzome AG, of Heidelberg, Germany, will soon become GlaxoSmithKline plc's newest platform technology asset, subsequent to the pharma's acquisition of all outstanding shares of Cellzome for £61 million (US$99 million) in cash. GSK currently owns 19.98 percent of Cellzome.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.